SAMSON PRINCE H

Mr. SAMSON PRINCE H


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Biomimetics
Verified
Journal Article
Open access
PDF file
ASAsma Musfira Shabbirahmed
Asma Musfira Shabbirahmed
Rajkumar SekarRajkumar Sekar
Rajkumar Sekar
LGLevin Anbu Gomez
Levin Anbu Gomez
MSMedidi Raja Sekhar
Medidi Raja Sekhar
SHSAMSON PRINCE H
SAMSON PRINCE H
Prathap SomuPrathap Somu
Prathap Somu
Regenerative medicine has received potential attention around the globe, with improving cell performances, one of the necessary ideas for the advancements of regenerative medicine. It is crucial to enhance cell performances in the physiological system for drug release studies because the variation in cell environments between in vitro and in vivo develops a loop in drug estimation. On the other hand, tissue engineering is a potential path to integrate cells with scaffold biomaterials and produce growth factors to regenerate organs. Scaffold biomaterials are a prototype for tissue production and perform vital functions in tissue engineering. Silk fibroin is a natural fibrous polymer with significant usage in regenerative medicine because of the growing interest in leftovers for silk biomaterials in tissue engineering. Among various natural biopolymer-based biomaterials, silk fibroin-based biomaterials have attracted significant attention due to their outstanding mechanical properties, biocompatibility, hemocompatibility, and biodegradability for regenerative medicine and scaffold applications. This review article focused on highlighting the recent advancements of 3D printing in silk fibroin scaffold technologies for regenerative medicine and tissue engineering.

22 January 2025 in Materials Advances
Verified
Journal Article
Open access
PDF file
SHSAMSON PRINCE H
SAMSON PRINCE H
DKDeepankumar Kanagavel
Deepankumar Kanagavel
Suckerin biomaterials offer elasticity, biocompatibility, and β-sheet self-assembly. Superior to other proteins, they excel in adaptability. Nanotechnology and succinylation boost drug delivery, tissue repair, and wound healing.

6 May 2024 in Environment, Development and Sustainability
Verified
Journal Article
Closed access
PDF file
ASAsma Musfira Shabbirahmed
Asma Musfira Shabbirahmed
Prathap SomuPrathap Somu
Prathap Somu
HYHsi-Hsien Yang
Hsi-Hsien Yang
SHSAMSON PRINCE H
SAMSON PRINCE H
CKChetan Shekhar Karua
Chetan Shekhar Karua
AYAkhilesh Kumar Yadav
Akhilesh Kumar Yadav

29 June 2026 in Journal of Biological Engineering
Verified
Journal Article
Open access
SHSAMSON PRINCE H
SAMSON PRINCE H
DRDinesh R. Rao
Dinesh R. Rao
PVPriyadharshini Velavan
Priyadharshini Velavan
TVThamizharasi Veeran
Thamizharasi Veeran
YSYukesh Kumar Sakthivel
Yukesh Kumar Sakthivel
KDKanagavel Deepankumar
Kanagavel Deepankumar
Osteoporosis is a systemic skeletal disorder characterized by impaired bone microarchitecture and reduced bone strength arising from dysregulated coupling between osteoclast-mediated resorption and osteoblast-driven formation. Estrogen deficiency, chronic inflammation, oxidative stress, and altered RANKL/OPG signaling amplify osteoclastogenesis while suppressing Wnt/β-catenin-dependent osteoblast differentiation, resulting in progressive trabecular thinning and cortical porosity. Although antiresorptive agents and anabolic therapies reduce fracture risk, they do not fully restore bone quality, microvascular integrity, or osteoimmune balance. Platelet-derived biomaterials (PDBs), including platelet-rich plasma, platelet-rich fibrin, platelet lysates, and platelet-based hydrogels, represent autologous bioactive systems enriched with platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, insulin-like growth factor-1, and bioactive lipid mediators. Upon activation, PDBs provide an early burst and sustained release of growth factors within a fibrin matrix that supports mesenchymal stem cell recruitment, RUNX2- and Osterix-mediated osteogenic differentiation, extracellular matrix deposition, and angiogenic coupling through VEGF-driven neovascularization. Concurrently, PDBs modulate osteoclast activity by influencing the RANKL/OPG axis, promoting macrophage polarization toward an M2 reparative phenotype, and attenuating inflammatory cytokine signaling. Integration of PDBs with osteoconductive scaffolds and nanostructured delivery platforms further enhances mechanical stability, local retention, and spatiotemporal biofactor presentation in osteoporotic bone defects. Preclinical evidence demonstrates improvements in bone mineral density, trabecular architecture, and fracture repair; emerging clinical applications in spinal fusion and fracture management suggest translational promise. However, variability in platelet concentration, activation protocols, and dosing standardization remains a barrier to widespread clinical adoption. PDB-based regenerative strategies therefore offer a mechanistically targeted and clinically adaptable approach to restoring skeletal integrity in osteoporosis.